NTRK1 and cancer: Despite the tremendous progress made in the last decades in deciphering the molecular intricacies of various signaling circuitries that operate aberrantly in cancers and the therapeutic advancement seen with some of the newer anti-cancer modalities recently approved by the FDA, such as humanized monoclonal antibodies directed at VEGF-A (vascular endothelial growth factor A) and receptor tyrosine kinases [1], [2] or non-peptide tyrosine kinase inhibitors [3], [4], the 5-year prognosis for most solid tumors remains reserved.